Serial analysis for the activating JAK2V617F mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation.
|Original language||English (US)|
|Number of pages||2|
|Publication status||Published - Mar 1 2006|
- Leukemic transformation
- Myelofibrosis with myeloid metaplasia
- Myeloproliferative disorders
ASJC Scopus subject areas